Efficacy and Safety of FTY720 for Acute Stroke


Phase 2 Results N/A

Eligibility Criteria

Inclusion Criteria

- Age 18-80 years
- Clinical presentation of spontaneous intracerebral hemorrhage/ischemic stroke
- MRI/MRA scan compatible with spontaneous intracerebral hemorrhage/ ischemic stroke
- Time to fty720 treatment< 72 h from symptom onset
- Glasgow Coma Score >6 on initial presentation or improvement to a Glasgow Coma Score >6 within the time frame for enrollment.
- Primary supratentorial ICH of ≥5cc and <30cc
- TOAST: Large-artery atherosclerosis

Exclusion Criteria

- Patients who will undergo surgical evacuation of intracerebral hemorrhage
- Inability to undergo neuroimaging with Magnetic Resonance
- Glasgow Coma Score < 6.
- Baseline modified Rankin Scale score >1
- Primary intraventricular hemorrhage ICH due to coagulopathy (PT > 15 s or International Normalized Ratio > 1.3, Partial Thromboplastin Time > 36) or trauma
- Thrombocytopenia: platelet count <100 000
- Clinically significant hepatic disease as demonstrated by history, clinical exam (ascites, varices), or laboratory findings (LFTs >2x normal, coagulopathy as described)
- Comorbid conditions likely to complicate therapy including but not limited to the following: a history of New York Heart Association class II, III, or IV Congestive Heart Failure; end-stage acquired immune deficiency syndrome
- Pregnancy
- Malignancy (history of or active)
- Bradyarrhythmia and Atrioventricular Block
- Concomitant use with antineoplastic,immunosuppressive or immune modulating therapies
- Macular Edema